Stock CPMV MOSAIC IMMUNOENGINEERING, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Mosaic ImmunoEngineering, Inc.

Equities

CPMV

US61945M1018

Delayed OTC Markets
Other stock markets
 11:20:30 2024-06-07 am EDT 		5-day change 1st Jan Change
0.5 USD 0.00% Intraday chart for Mosaic ImmunoEngineering, Inc. +19.05% -16.67%
May. 14 Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 19 Mosaic Immunoengineering, Inc. Announces Demise of Gloria Felcyn, Independent Director and Member of Audit Committee, Compensation Committee and Corporate Governance and Nominating Committee CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.
AQ
Mosaic ImmunoEngineering : Termination of Material Agreement - Form 8-K
PU
MOSAIC IMMUNOENGINEERING INC. : Change in Directors or Principal Officers (form 8-K)
AQ
MOSAIC IMMUNOENGINEERING INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Mosaic ImmunoEngineering : Newly Published Data Further Support Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma
PU
MOSAIC IMMUNOENGINEERING INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation
PU
Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference
PU
Spotlight Presentation at the World Molecular Imaging Congress Highlights Mosaic ImmunoEngineering’s Immuno-Oncology and Modular Vaccine Platform Candidates
PU
MOSAIC IMMUNOENGINEERING : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Mosaic ImmunoEngineering : Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors (Form 8-K)
PU
MOSAIC IMMUNOENGINEERING INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Mosaic ImmunoEngineering : Form of Convertible Note Purchase Agreement (Form 8-K)
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CPMV Stock
  4. News Mosaic ImmunoEngineering, Inc.
  5. Press Releases